Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.99 HKD | -0.99% | +8.73% | -19.84% |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The group shows a rather high level of debt in proportion to its EBITDA.
- Most analysts recommend that the stock should be sold or reduced.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.84% | 1.45B | B- | ||
+26.08% | 662B | C+ | ||
+22.46% | 546B | B | ||
-4.77% | 359B | C+ | ||
+16.97% | 323B | B- | ||
+5.69% | 289B | C+ | ||
+13.68% | 234B | B+ | ||
+4.34% | 198B | B- | ||
-10.92% | 194B | A+ | ||
+8.08% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 2186 Stock
- Ratings Luye Pharma Group Ltd.